Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05608382
Other study ID # SGW2022
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 7, 2022
Est. completion date March 18, 2022

Study information

Verified date October 2022
Source Center for Innovation and Research Organization
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. Efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 18, 2022
Est. primary completion date March 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: A subject may be eligible for study participation if all of the following criteria are met: 1. Subject is male or female greater than 18 years of age. 2. Subject does not have a history of skin allergies/atopia (e.g. atopic dermatitis). 3. Subject does not have a history of skin disease (e.g scleroderma, vitiligo, psoriasis) or a chronic systemic disease affecting the skin (e.g systemic lupus erythematosus). 4. Subject is willing to have materials applied and follow the protocol. 5. Subject agrees to avoid exposure of the test sites to the sun, chemical product, clothes and to refrain from touching the area of application (for T0 [baseline], T1 [5 minutes], T2 [2 hours]). 6. Subject agrees to refrain from getting a bath/shower before T3 (24 h). 7. Subject agrees to avoid scrubbing, applying, and/or washing the test area with new soap, moistures, powders, lotions, cosmetic or toiletry products during the study. 8. Subject is able to follow directions as outlined in the protocol and anticipates being available for all study visits. 9. Subject is willing to participate in all study evaluations. 10. Subject is in generally good health. 11. Subject is willing to sign the Informed Consent form prior to study participation Exclusion Criteria: 1. Female subject is pregnant, nursing, planning a pregnancy, or not using adequate birth control. 2. Subject is immunologically compromised or has received specific topical treatment (antimicrobial or not-antimicrobial), during the last month. 3. Subject reports a history of allergies to antiseptics. 4. Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study. 5. Subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs.

Study Design


Intervention

Other:
sterile Phosphate Buffer Saline
control group
SGW13
active comparator

Locations

Country Name City State
United States Center for Innovation and Research Organization Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Center for Innovation and Research Organization

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Colony Forming Unit (CFU) count Comparison of the number of CFUs counted for each treatment arm 5 minutes
Primary Colony Forming Unit (CFU) count Comparison of the number of CFUs counted for each treatment arm 2 hours
Primary Colony Forming Unit (CFU) count Comparison of the number of CFUs counted for each treatment arm 24 hours
See also
  Status Clinical Trial Phase
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT00210899 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Completed NCT00761215 - Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections Phase 2
Completed NCT00228982 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Completed NCT01967225 - Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections Phase 3
Withdrawn NCT00990392 - Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections N/A
Completed NCT00228410 - Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections Phase 3
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT02276482 - Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) Phase 3
Completed NCT00198679 - Effect of Chlorhexidine Skin Cleansing on Skin Flora Phase 4
Completed NCT03981822 - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts Phase 2
Completed NCT00711802 - Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections Phase 4
Completed NCT00488761 - Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI Phase 4
Completed NCT00679302 - Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management Phase 4
Completed NCT00257036 - A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin Phase 2/Phase 3
Completed NCT04485676 - Dalbavancin in Real Clinical Practice in Spain
Completed NCT00785200 - MRSA Colonization and Control in the Dallas County Jail N/A
Completed NCT00257062 - A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin Phase 3
Completed NCT02582203 - Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA Phase 4
Completed NCT00388310 - Effective Antibiotic Treatment of MRSA N/A